The Globe and Mail’s Sophi.io Wins WAN-IFRA’s North American Digital Media Award

TORONTO, July 06, 2021 (GLOBE NEWSWIRE) — Sophi.io, The Globe and Mail’s artificial intelligence-based automation, optimization and prediction engine, won WAN-IFRA’s 2021 North American Digital Media Award in the category of Best Paid Content Strategy. This is Sophi’s fourth award in the last month. The North American Digital Media Awards honour news publishers that have delivered […]

TORONTO, July 06, 2021 (GLOBE NEWSWIRE) — Sophi.io, The Globe and Mail’s artificial intelligence-based automation, optimization and prediction engine, won WAN-IFRA’s 2021 North American Digital Media Award in the category of Best Paid Content Strategy. This is Sophi’s fourth award in the last month.

The North American Digital Media Awards honour news publishers that have delivered cutting-edge, unique and original digital media projects in the past year.

“Through the use of this [dynamic paywall] technology, The Globe and Mail truly understands its readers’ habits, leading to best practices in advertising and paid content, smartly adjusting their business strategy,” WAN-IFRA said when announcing the decision.

Phillip Crawley, CEO and Publisher of The Globe and Mail, said: “Winning a WAN-IFRA North American Digital Media Award for the second year in a row demonstrates Sophi’s ability to show the publishing industry what the future looks like. We are proud to be able to bring these AI and ML-powered tools to organizations across the globe.”

Sophi was developed by The Globe and Mail to help the newsroom make important strategic and tactical decisions. It is a suite of tools that includes Sophi Automation and Sophi for Paywalls as well as Sophi Analytics, a newsroom decision-support system.

Sophi is an artificial-intelligence system that helps publishers identify and leverage their most valuable content. It has powerful predictive capabilities – using natural language processing, Sophi Dynamic Paywall is a fully dynamic, real-time, personalized paywall engine that analyzes both content and user behaviour to determine when to ask a reader for money or an email address, and when to leave them alone.

As the North American award winner, Sophi is now a contender for the WAN-IFRA World Digital Media Awards, where the winners from North America, Latin America, Asia, Europe, Africa, India, and the Middle East compete.

About Sophi.io

Sophi.io (https://www.sophi.io) is a suite of AI-powered optimization and prediction tools developed by The Globe and Mail, Canada’s foremost news media company, to help content publishers make important strategic and tactical decisions. Sophi solutions range from Sophi Site Automation and Sophi for Paywalls to Sophi Analytics, a decision-support system for content publishers. Sophi is designed to improve the metrics that matter most to any business, such as subscriber retention and acquisition, engagement, recency, frequency and volume.

Contact

Jamie Rubenovitch
Head of Marketing, Sophi.io
The Globe and Mail
416-585-3355
jrubenovitch@globeandmail.com

 

Previous Article

ADDRESS BY HIS EXCELLENCY PRIME MINISTER HASSAN DIAB DURING AMBASSADORS’ MEETING AT GRAND SERAIL

Next Article

Seegene announces partnership with Bio-Rad to develop diagnostic testing products for the U.S. Market

Related Posts

Xi inspects major forest farm in north China’s Hebei

BEIJING, Aug. 25, 2021 /PRNewswire/ — A report from CCTV+: Chinese President Xi Jinping on Monday inspected a major forest farm in Chengde City of north China’s Hebei Province, hearing reports on ecological conservation and forestry management, and checking the growth of forest woods. At the Saihanba Mechanical Forest Farm, Xi observed the natural landscape, […]

Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa

BERLIN, CAIRO and DUBAI, UAE, Nov. 30, 2022 /PRNewswire/ — Bioventure, a Dubai-based pharmaceutical company, Minapharm Pharmaceuticals, a Cairo-based pharmaceutical company, and MiGenTra GmbH, a Berlin-based pharmaceutical company, announced today the signing of an exclusive license agreement for the commercialization of multiple biosimilar candidates developed and manufactured by Alvotech, in Egypt and eighteen additional countries […]